Kodiak Sciences Inc.

KOD · Nasdaq · United States

Share price · KOD

$97.81+57.16 (+140.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 745K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KOD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026+178.0%
  2. 26 Mar 2026+74.8%
  3. 30 Jan 2026-10.5%

    Nothing announced by KOD that day or the session before.

Share of unusual movement by asset

For each asset, the share of KOD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tabirafusp alfa
events and moves
6shown from 8 days
Tabirafusp tedromer
events and moves
3shown from 8 days
Tarcocimab tedromer
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—66%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—32%

Assets

(3 total)
3Total Assets
0Approved
3Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
VEGF + IL-6Multispecific antibody
Indication not yet linked
Phase 3
VEGF + IL-6Multispecific antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Tabirafusp alfaPhase 3Macular Edema Secondary to Inflammation
Est. primary completion 2027-02 · NCT06996080 · CT.gov ↗
What to watch
April 2027 (1)
Tabirafusp alfaPhase 3Macular Edema Secondary to Inflammation
Est. primary completion 2027-04 · NCT06990399 · CT.gov ↗
What to watch
2028 (1)
August 2028 (1)
Tabirafusp tedromerPhase 3Diabetic Macular Edema (DME)
Est. primary completion 2028-08-31 · NCT07734844 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 September 2026Topline resulttabirafusp-ted (KSI-501)DAYBREAK Phase 3 topline: tabirafusp-ted met its primary endpoint
Kodiak Sciences Inc. · Source ↗
28 September 2026Topline resultTarcocimab tedromerDAYBREAK Phase 3 (NCT06556368) met its primary endpoint
Kodiak Sciences · Source ↗
26 March 2026Topline resultTarcocimab tedromerGLOW2 (NCT06270836) Phase 3 met its primary endpoint
Kodiak Sciences Inc. · Source ↗
July 2023Topline resultTarcocimab tedromerGLEAM and GLIMMER Phase 3 miss their primary endpoints
Kodiak Sciences Inc. · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$58M$89M$66M-$44M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$56M$126M$66M-$46M operating cash flowreport ↗
2026-Q1—$49M$170M$58M-$40M operating cash flowreport ↗
2025-Q3—$50M$72M$61M-$33M operating cash flowreport ↗
2025-Q2—$43M$104M$54M-$35M operating cash flowreport ↗
2025-Q1—$44M$139M$57M-$29M operating cash flowreport ↗
2024-Q3—$32M$198M$44M-$21M operating cash flowreport ↗
2024-Q2—$33M$219M$45M-$26M operating cash flowreport ↗
2024-Q1—$30M$246M$43M-$40M operating cash flowreport ↗
2023-Q3—$36M$346M+ $0 short-term inv.$50M-$33M operating cash flowreport ↗
2023-Q2—$67M$379M+ $0 short-term inv.$80M-$42M operating cash flowreport ↗
2023-Q1—$57M$317M+ $105M short-term inv.$71M-$47M operating cash flowreport ↗
2022-Q3—$62M$178M+ $359M short-term inv.$77M-$53M operating cash flowreport ↗
2022-Q2—$74M$173M+ $425M short-term inv.$91M-$55M operating cash flowreport ↗
2022-Q1—$76M$672M$96M-$43M operating cash flowreport ↗
2021-Q4——$732M+ $0 short-term inv.$93M-$59M operating cash flowreport ↗
2021-Q3—$56M$799M$68M-$52M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$182M$210M$57M-$136M operating cash flowreport ↗

Kodiak Sciences did not disclose revenue for 2025. R&D expenses were $182.37M, up 44.6% YoY, and the company ended the year with $209.86M in cash and cash equivalents. The full-year net loss was $229.97M.

The company reported positive Phase 3 topline results from GLOW2, showing Zenkuda (tarcocimab tedromer) was superior to sham in diabetic retinopathy, and said it plans to accelerate toward a multi-indication Biologics License Application submission. Enrollment has completed in the Phase 3 DAYBREAK study of Zenkuda and KSI-501 in wet AMD, with topline data expected in September 2026; topline results for the KSI-101 Phase 3 PEAK and PINNACLE studies are expected in 4Q 2026 and 2Q 2027, respectively. In December 2025, Kodiak completed an equity offering with net proceeds of $173.0M, and management stated that current cash supports planned operations into 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$126M$168M$44M-$117M operating cash flowreport ↗
2023-FY—$206M$286M+ $0 short-term inv.$65M-$154M operating cash flowreport ↗
2022-FY—$268M$190M+ $289M short-term inv.$83M-$206M operating cash flowreport ↗
2021-FY—$217M$732M+ $0 short-term inv.$67M-$182M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 88 purchases ($241.3M), 14 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerOpen-market purchase4,703$98.51$463KForm 4
2026-11-05BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerOpen-market purchase81,729$98.51$8.1MForm 4
2026-11-04BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerOpen-market purchase8,742$98.51$861KForm 4
2026-11-04BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerOpen-market purchase151,916$98.51$15.0MForm 4
2026-10-23Yang Taiyin · directorOption exercise20,000$2.35$47KForm 4
2026-10-23Yang Taiyin · directorOption exercise (derivative)20,000——Form 4
2026-10-21BORGESON JOHN A. · Chief Financial OfficerOption exercise30,000$2.49$75KForm 4
2026-10-21BORGESON JOHN A. · Chief Financial OfficerOpen-market sale8,514$87.67$746KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 187 reporting institutions held 58.0M shares ($2.1B, 88.7% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP19,919,186$759.3M
2BlackRock, Inc.3,935,302$150.0M
3STATE STREET CORP2,250,920$85.8M
4BRAIDWELL LP1,818,665$69.3M
5VANGUARD CAPITAL MANAGEMENT LLC1,717,076$65.5M
6GOLDMAN SACHS GROUP INC1,689,003$64.4M
7RTW INVESTMENTS, LP1,487,934$56.7M
8TCG Crossover Management, LLC1,445,538$55.1M
9Boxer Capital Management, LLC1,361,000$51.9M
10JANUS HENDERSON GROUP PLC1,325,457$50.5M
11ICONIQ Capital, LLC1,266,563$48.3M
12Ikarian Capital, LLC1,265,795$48.3M
13GEODE CAPITAL MANAGEMENT, LLC1,000,411$38.1M
14SILVERARC CAPITAL MANAGEMENT, LLC991,930$37.8M
15CITADEL ADVISORS LLC870,788$33.2M